LOS ANGELES, November 8, 2026 — RadNet, Inc. (NASDAQ: RDNT), a national leader in high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, reported record quarterly revenue and Adjusted EBITDA for the third quarter of 2026 and raised selected full-year guidance ranges, according to a press release issued via GlobeNewswire on November 8, 2026.

Third-Quarter 2026 Results at a Glance

• Total company revenue increased 22.1% to $638.3 million, from $522.9 million in the third quarter of 2025.
• Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 32.6% to $32.9 million, from $24.8 million in the third quarter of 2025.
• Total company Adjusted EBITDA (1) rose 23.8% to $105.0 million, from $84.9 million in the third quarter of 2025.
• Digital Health reportable segment Adjusted EBITDA (1) declined 11.8% to $3.0 million, from $3.5 million in the third quarter of 2025.
• Total company Adjusted EBITDA (1) margin expanded to 16.5%, from 16.2% in the third quarter of 2025.
• Adjusted for unusual or one-time items in the quarter, adjusted diluted earnings per share (3) was $0.30, versus $0.24 in the third quarter of 2025.
• Aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 19.9%, and same-center advanced imaging procedural volumes rose 8.9%, compared with the third quarter of 2025.
• As of September 30, 2026, the company held a cash balance of $750.6 million, with a net debt to Adjusted EBITDA (1) ratio of 1.66x.
• RadNet raised its full-year 2026 guidance ranges for Imaging Center revenue, Adjusted EBITDA (1) and free cash flow (2), and lifted its Digital Health Adjusted EBITDA (1) guidance range.

Record Quarter, Driven by Capacity Expansion and Advanced Imaging Mix

“We delivered record quarterly Revenue and Adjusted EBITDA (1) in the third quarter. Total Company Revenue grew 22.1% and Adjusted EBITDA (1) grew 23.8% compared with last year’s third quarter, and Adjusted EBITDA (1) margin expanded 23 basis points. These results were driven by continued initiatives to create and fill capacity at existing imaging centers, new center openings, the continued shift in the business mix towards advanced imaging, tuck-in acquisitions, improved reimbursement from commercial payors, the expansion of our health system joint ventures and 32.6% Revenue growth in the Digital Health segment,” said Dr. Howard Berger, President and Chief Executive Officer of RadNet.

“Advanced imaging growth continues to be strong, both in aggregate and on a same-center basis. Compared with last year’s third quarter, aggregate advanced imaging procedural volumes increased 19.9% and same-center advanced imaging procedural volumes increased 8.9%. As a result, RadNet’s advanced imaging business mix increased 232 basis points, from 28.2% of all procedures in the third quarter of 2025 to 30.6% in the third quarter of 2026,” he continued.

For readers sizing up the company, RadNet describes itself as the leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on the number of locations and annual imaging revenue, with imaging center markets spanning Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia and — together with contracted radiologists and inclusive of full-time and per diem employees and technologists — more than 12,000 team members. Within that footprint, the advanced imaging shift is playing out inside existing centers as well: same-center advanced imaging volumes rose 8.9% while overall same-center volume, which includes routine exams such as x-ray and ultrasound, rose 3.2%, and because same-center figures count only centers that were part of RadNet in both periods, the higher advanced imaging growth indicates the mix shift is occurring within the existing installed base, not solely through acquisitions or new center openings.

Guidance Raised Again as ONRAD Deal Draws Interest

“With strong performance across nearly every part of the core imaging center business, we are again raising certain guidance ranges in anticipation that full-year results will exceed both our original expectations and the revised ranges issued in conjunction with first and second quarter 2026 results. We are raising 2026 Imaging Center guidance ranges for Revenue, Adjusted EBITDA (1) and Free Cash Flow (2),” added Dr. Berger.

Dr. Berger also pointed to the company’s recently announced pending acquisition of ONRAD as a source of future growth: “We are particularly excited about the opportunities for growth and expansion that will be made possible as a result of the recently announced pending acquisition of ONRAD. The inbound interest from current joint venture partners and potential new partners and customers has exceeded our expectations. The strategic fit that ONRAD’s capabilities have with both RadNet’s core imaging center business and Digital Health solutions is already being recognized in the imaging marketplace, and we look forward to the opportunities that could result once the acquisition is closed.”

“RadNet’s balance sheet remains healthy and continues to provide the operating flexibility necessary to achieve further growth. We ended the third quarter with $750.6 million in cash and a Net Debt to Adjusted EBITDA (1) leverage ratio of 1.66x. This liquidity enables us to keep investing in organic growth and to pursue attractive strategic acquisitions in the coming quarters,” he concluded.

For readers tracking what comes next, the near-term markers are concrete: the closing of the still-pending ONRAD acquisition, which management tied to future growth and expansion opportunities, and the November 9 conference call, where Dr. Berger and Executive Vice President and Chief Financial Officer Mark Stolper will discuss the quarter. Management also stated its expectation that full-year results will exceed both original expectations and the ranges revised after the first and second quarters of 2026 — a projection that year-end reporting will test.

Detailed Third-Quarter Financial Results

For the third quarter of 2026, RadNet reported total company revenue of $638.3 million and Adjusted EBITDA (1) of $105.0 million. Revenue increased $115.4 million, or 22.1%, and Adjusted EBITDA (1) increased $20.2 million, or 23.8%, compared with the third quarter of 2025.

The Digital Health reportable segment posted revenue (inclusive of intersegment revenue) of $32.9 million and Adjusted EBITDA (1) of $3.0 million. Segment revenue increased $8.1 million, or 32.6%, while segment Adjusted EBITDA (1) decreased $0.4 million, or 11.8%, versus the prior-year quarter.

That divergence between segment revenue growth and segment profitability sits alongside the company’s disclosed investment lines: among the quarter’s noteworthy items, RadNet flagged $7.3 million of intangibles amortization related to the Digital Health operating segment and $5.6 million of non-capitalized research and development expense tied to the DeepHealth Cloud OS and AI solutions.

Before adjusting for unusual or one-time items, total company net income for the third quarter of 2026 was $4.2 million, compared with net income of $5.4 million in the third quarter of 2025. Fully diluted net income per share was $0.05, versus $0.07 a year earlier, based on weighted average diluted shares outstanding of 79.2 million in the third quarter of 2026 and 77.4 million in the third quarter of 2025.

A number of unusual, one-time and noteworthy items affected the quarter:

• $1.2 million in severance expense related to cost-savings initiatives;
• a $7.5 million gain on the contribution of imaging centers into joint ventures;
• $0.6 million of expense related to leases for de novo facilities under construction that have yet to open their operations;
• a $5.4 million loss on the disposal of equipment;
• $7.3 million of intangibles amortization expense related to the Digital Health operating segment;
• $5.6 million of non-capitalized research and development expenses related to the DeepHealth Cloud OS and AI solutions;
• $2.8 million in legal settlements;
• $2.7 million of acquisition transaction costs;
• an $8.3 million non-cash change in contingent consideration; and
• $2.1 million of lease abandonment charges.

Adjusting for these items, total company Adjusted Earnings (3) was $23.8 million, and diluted Adjusted Earnings Per Share (3) was $0.30 in the third quarter of 2026, compared with total company Adjusted Earnings (3) of $18.8 million and diluted Adjusted Earnings Per Share (3) of $0.24 in the third quarter of 2025.

Procedure volumes continued to climb. Compared with the third quarter of 2025, MRI volume increased 18.3%, CT volume increased 22.0% and PET/CT volume increased 30.4%. Overall volume, including routine imaging exams such as x-ray, ultrasound, mammography and other exams, increased 10.8% year over year. On a same-center basis — counting only centers that were part of RadNet in both the third quarters of 2026 and 2025 — MRI volume increased 8.2%, CT volume increased 10.2% and PET/CT volume increased 8.2%, while overall same-center volume, inclusive of routine imaging exams, increased 3.2%.

First Nine Months of 2026

For the first nine months of 2026, RadNet reported total company revenue of $1,836.6 million and Adjusted EBITDA (1) of $268.0 million. Revenue increased $344.1 million, or 23.1%, and Adjusted EBITDA (1) increased $55.4 million, or 26.1%, compared with the first nine months of 2025.

The Digital Health segment generated revenue (inclusive of intersegment revenue) of $94.5 million and Adjusted EBITDA (1) of $6.8 million over the period. Revenue increased $29.7 million, or 45.8%, while Adjusted EBITDA (1) decreased $3.7 million, or 35.4%, versus the first nine months of 2025.

Unadjusted for one-time or unusual items, the company recorded a total company net loss of $21.8 million for the first nine months of 2026, compared with a total company net loss of $18.1 million in the corresponding 2025 period. Fully diluted net loss per share was $(0.28), versus $(0.24), based on weighted average diluted shares outstanding of 77.6 million for the 2026 nine-month period and 74.7 million for the 2025 period.

Revised 2026 Guidance

RadNet amended its previously announced full-year 2026 guidance levels, raising the Imaging Center segment’s ranges for revenue, Adjusted EBITDA (1) and free cash flow (2), and lifting the Digital Health segment’s Adjusted EBITDA (1) range. Within the revised guidance, free cash flow is measured net of proceeds from the sale of equipment and of New Jersey Imaging Network L.L.C. joint venture capital expenditures, and interest-related amounts are net of payments received from counterparties on interest rate swaps and of interest income from the company’s cash balance recorded in Other Income.

“The Imaging Center segment has outperformed projections in each of the first three quarters of this year. As a result, we are raising its guidance ranges for Revenue, Adjusted EBITDA (1) and Free Cash Flow (2). In the Digital Health segment, we are raising the Adjusted EBITDA (1) guidance range as a result of effective expense management and faster-than-projected integration of acquired operations,” Dr. Berger explained.

Conference Call on November 9

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss the third-quarter 2026 results on Monday, November 9, 2026, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

• Date: Monday, November 9, 2026
• Time: 10:30 a.m. Eastern Time
• Dial-in number: 844-744-1280
• International dial-in number: 412-564-6465

Participants are recommended to dial in approximately five minutes prior to the start of the 10:30 a.m. call. Simultaneous and archived webcasts will be available at or via under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, using the passcode 10213035.

About RadNet, Inc.

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue, with a network of owned and/or operated outpatient imaging centers. Its imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. RadNet also provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, along with teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Additional information is available at www.radnet.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of current beliefs, expectations and assumptions regarding the future of the business, future plans and strategies, projections, and anticipated future conditions, events and trends. They can generally be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements in this release include, among others, statements about anticipated business results, balance sheet and liquidity, future liquidity, burn rate and the continuing ability to service or refinance current indebtedness.

Forward-looking statements are neither historical facts nor assurances of future performance. Because they relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside of the company’s control. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause actual results and financial condition to differ materially include, among others:

• the availability and terms of capital to fund the business;
• the ability to service indebtedness, make principal and interest payments as those payments become due, remain in compliance with applicable debt covenants, and refinance such indebtedness on acceptable terms;
• changes in general economic conditions nationally and regionally in the markets in which the company operates;
• the availability and terms of capital to fund the expansion of the business and improvements to existing facilities;
• the ability to maintain the current credit rating and the impact on funding costs and competitive position if it does not;
• the ability to acquire, develop, implement and monetize technology, digital health initiatives, artificial intelligence algorithms and applications;
• volatility in interest and exchange rates, or credit markets;
• the adequacy of cash flow and earnings to fund current and future operations;
• changes in service mix, revenue mix and procedure volumes;
• delays in receiving payments for services provided;
• increased bankruptcies among partner physicians or joint venture partners;
• the impact of the political environment and related developments on the current healthcare marketplace and on the business, including with respect to the future of the Affordable Care Act;
• the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for services, or other material impacts to the business;
• closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting operations or suppliers’ abilities to deliver supplies needed in facilities;
• the occurrence of hostilities, political instability or catastrophic events;
• the emergence or reemergence of, and effects related to, future pandemics, epidemics and infectious diseases; and
• noncompliance with any privacy or security laws, or any cybersecurity incident or other security breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.

Any forward-looking statement is based on information currently available and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

GAAP and Non-GAAP Financial Information

This release contains certain financial information not reported in accordance with GAAP. The company uses both GAAP and non-GAAP metrics to measure its financial results and believes that, in addition to GAAP metrics, these non-GAAP metrics assist in measuring cash-based performance. The company considers this information useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the company’s financial condition against other quarters. Such information should not be considered a substitute for any measures calculated in accordance with GAAP and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in the tables accompanying the release.

Investor and Media Contact

RadNet, Inc. — Mark Stolper, Executive Vice President and Chief Financial Officer, 310-445-2800.

Notes on Non-GAAP Financial Measures

(1) The company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations, adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash, extraordinary and one-time events taking place during the period. Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. It is a non-GAAP financial measure used as an analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from it should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities, or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(2) The company defines free cash flow as Adjusted EBITDA less total capital expenditures (whether completed with cash or financed) and cash interest expense. Free cash flow is a non-GAAP financial measure. The company uses free cash flow because it believes it provides useful information for investors and management by measuring the capacity to generate cash from operating activities. Free cash flow does not represent total cash flow, since it does not include cash flows generated by or used in financing activities, and the company’s definition may differ from definitions used by other companies. Free cash flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities, or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Because free cash flow is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(3) The company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders, excluding losses or gains on the disposal of equipment, losses on debt extinguishments, bargain purchase gains, severance costs, losses on impairment, losses or gains on swap valuation, gains on extinguishment of debt, unusual or non-recurring entries that impact the company’s tax provision, and any other non-recurring or unusual transactions recorded during the period. Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure and is a non-GAAP financial measure used as an analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from it should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities, or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Because Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

Source: RadNet, Inc. press release via GlobeNewswire, November 8, 2026. Original release